Vivos Therapeutics, Inc.
VVOSHealthcareNASDAQMedical Devices · Last scanned Sep 5, 2026
Scan Results
Daily timeframeVivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and. With a market capitalization of $3.7M, it sits in micro-cap territory. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
Market Cap
$3.7M
Beta
6.00
P/E (TTM)
—
P/E (Fwd)
-0.23
EPS (TTM)
$-2.00
EPS (Fwd)
$-0.82
ROE
-8585.3%
ROA
-56.2%
Cash
$1.8M
Total Debt
$12.5M
Free CF
-$8.5M
52W Change
-95.4%
Annual Financials
Cash vs Debt
Where VVOS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VVOS finished 79.76% below its 150-day moving average ($0.84) and 85.22% below its 200-day moving average ($1.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VVOS overbought or oversold?
At the September 3, 2026 close, VVOS's RSI(14) was 25.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, VVOS has $1.8M in cash with $12.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$8.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -8585.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $16.0M (2022) to $17.4M (2025).
A beta of 6.00 means VVOS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Vivos Therapeutics, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vivos Therapeutics, Inc. and its sector.